AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Ensysce Biosciences Inc. (ENSC)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.23

-0.07 (-1.11%)

At close: Feb 07, 2025, 3:58 PM

6.14

-1.37%

After-hours Feb 07, 2025, 05:06 PM EST

undefined% (undefined)

Bid	6.08
Market Cap	8.12M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-29.1
PE Ratio (ttm)	-0.21
Forward PE	n/a
Analyst	Buy

Ask	6.55
Volume	13,503
Avg. Volume (20D)	145,296
Open	6.40
Previous Close	6.30
Day's Range	6.06 - 6.40
52-Week Range	2.12 - 17.63
Beta	undefined

About ENSC

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 14, 2018

Employees 7

Stock Exchange NASDAQ

Ticker Symbol ENSC

Website https://www.ensysce.com

Analyst Forecast

According to 1 analyst ratings, the average rating for ENSC stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Ensysce Biosciences Inc. is scheduled to release its earnings on Mar 14, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+14.48%

Ensysce Biosciences shares are trading higher afte... Unlock content with Pro Subscription

2 months ago

+5.14%

Ensysce Biosciences shares are trading higher after the company reported better-than-expected Q3 financial results.

News

3 days ago · accessnewswire.com

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

~ Positive Enrollment Progress and Safety Data ~ ~ FDA Attention Establishes Momentum in the Pain Treatment Space ~ SAN DIEGO, CA / ACCESS Newswire / February 5, 2025 / Ensysce Biosciences, Inc. (NASD...

2 weeks ago · accessnewswire.com

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or...